GENVEC ADDING THREE GENE THERAPY VECTOR APPROACHES VIA THERAGEN
Executive Summary
GENVEC ADDING THREE GENE THERAPY VECTOR APPROACHES VIA THERAGEN merger announced April 20. GenVec will be "in the unique position among gene therapy companies in its ability to screen and test gene product candidates in all four of the most widely used and studied vector systems," the company said. GenVec has been developing therapies based on in vivo delivery of adenovirus, while Theragen has been emphasizing research using the herpes simplex virus. Theragen also has conducted research with adeno- associated virus and liposomes.